NCT02992678

Pentoxifylline for the Prevention of PEP

Prophylactic Treatment Pentoxifylline for the Prevention of Post-ERCP Pancreatitis

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Anhui Provincial Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Between December 2016 and June 2017, 110 consecutive patients older than 18 years who are scheduled to undergo diagnostic or therapeutic ERCP at the Anhui Provincial Hospital will be recruited for the study. Patients were randomized using opaque, sealed envelopes containing random numbers assigning them to treat with pentoxifylline (pentoxifylline group) or Placebo (placebo group) for preventing ERCP pancreatitis.

Conditions

• Pancreatitis

Interventions

Type	Name	Description
DRUG	Pentoxifylline	Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
DRUG	Placebo	Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.

Timeline

• Start date: 2016-12-01
• Primary completion: 2017-06-01
• Completion: 2017-09-01
• First posted: 2016-12-14
• Last updated: 2016-12-14

Locations

1 site across 1 country: China